Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Intermittent androgen deprivation.

N A Dawson1

  • 1Division of Hematology/Oncology, University of Maryland Greenebaum Cancer Center, 22 South Greene Street, Baltimore, MD 21201-1595, USA. ndawson@umgcc.umaryland.edu

Current Oncology Reports
|December 21, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Exploratory subgroup analyses of EV-302: a phase III global study to evaluate enfortumab vedotin in combination with pembrolizumab versus chemotherapy in previously untreated locally advanced or metastatic urothelial carcinoma.

ESMO open·2025
Same author

A randomized phase IIa study of quantified bone scan response in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 dichloride alone or in combination with abiraterone acetate/prednisone or enzalutamide.

ESMO open·2021
Same author

Epothilones in prostate cancer: review of clinical experience.

Annals of oncology : official journal of the European Society for Medical Oncology·2007
Same author

The management of localized prostate cancer.

Prostate cancer and prostatic diseases·2002
Same author

New agents for the treatment of renal cell carcinoma.

Expert review of anticancer therapy·2002
Same author

A randomized study comparing standard versus moderately high dose megestrol acetate for patients with advanced prostate carcinoma: cancer and leukemia group B study 9181.

Cancer·2000
Same journal

Next-Generation Checkpoint Combinations: Optimizing PD-(L)1-Based Therapy Across the Advanced, Adjuvant, and Neoadjuvant Settings.

Current oncology reports·2026
Same journal

Revisiting the Immunological Landscape of Locoregional Therapies for Gastrointestinal Cancers: A Shift Toward Interventional Immuno-Oncology.

Current oncology reports·2026
Same journal

Anti-PD-1 Combinations: Triplets and Beyond.

Current oncology reports·2026
Same journal

Sacituzumab Tirumotecan Across Gynecologic Malignancies: One Target, Multiple Diseases.

Current oncology reports·2026
Same journal

Clusterin in Head and Neck Squamous Cell Carcinoma: Diagnostic, Prognostic, and Therapeutic Implications.

Current oncology reports·2026
Same journal

Cardiac Risk Without a Roadmap: Lack of Evidence-Based Guidance for Cardiovascular Toxicity of T-Cell Redirecting Therapies.

Current oncology reports·2026
See all related articles

Intermittent androgen deprivation therapy offers potential benefits for prostate cancer patients, including improved quality of life. Ongoing trials will determine its role compared to continuous therapy.

Area of Science:

  • Oncology
  • Urology

Background:

  • Intermittent androgen deprivation (IAD) is an evolving strategy for prostate cancer management.
  • Its efficacy and impact on quality of life require further investigation.

Purpose of the Study:

  • To review the current evidence for intermittent androgen deprivation in prostate cancer.
  • To discuss preclinical and clinical findings, and ongoing trials.

Main Methods:

  • Review of preclinical studies in animal models.
  • Analysis of Phase II clinical trials assessing quality of life and sexual function.
  • Discussion of ongoing Phase III trials comparing IAD with continuous androgen deprivation.

Main Results:

  • Preclinical models show delayed prostate-specific antigen (PSA) progression and androgen independence with IAD.

Related Experiment Videos

  • Phase II trials indicate improved sexual function and quality of life for patients on IAD.
  • Patients typically spend 37%-58% of treatment time off androgen deprivation and respond to retreatment.

    • Conclusions:

    • Intermittent androgen deprivation demonstrates potential benefits in preclinical and early clinical studies.
    • Ongoing Phase III trials are crucial to establish its comparative effectiveness and survival impact.
    • Currently, IAD is considered an experimental approach in prostate cancer management.